Details

Autor(en) / Beteiligte

• James, W. Philip T
• Caterson, Ian D
• Coutinho, Walmir
• Finer, Nick
• Van Gaal, Luc F
• Maggioni, Aldo P
• Torp-Pedersen, Christian
• Sharma, Arya M
• Shepherd, Gillian M
• Rode, Richard A
• Renz, Cheryl L

Titel

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

Ist Teil von

• The New England journal of medicine, 2010-09, Vol.363 (10), p.905-917

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• In this clinical trial, the appetite suppressant sibutramine as compared with placebo resulted in modest weight loss but also in an unexpected increase in the risk of nonfatal myocardial infarction and stroke (a finding limited to patients with preexisting cardiovascular disease). Sibutramine should not be used in patients with cardiovascular disease. Obesity and excess weight are escalating public health concerns because they increase the prevalence of associated conditions such as diabetes mellitus and the risk of premature death. 1 , 2 More than 80% of even highly motivated patients are unable to achieve weight loss with dietary and lifestyle modifications alone. 3 Sibutramine is a norepinephrine and serotonin reuptake inhibitor that was approved for weight management in patients who are unable to lose weight by means of diet and exercise alone. Sibutramine induces satiety (resulting in reduced food intake) and an increase in energy expenditure. 4 , 5 In some patients, sibutramine increases blood pressure, pulse . . .